The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the ...

ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

In ANI's New Day trial, patients were randomized to an induction phase to receive either a single Iluvien injection or a series of five monthly injections of aflibercept, followed by supplemental ...

Alimera had in-licensed Iluvien from pSivida ( PSDV) in Feb 2005. As per the agreement, Alimera holds the worldwide rights to develop and sell Iluvien. With this approval, ...

LAS VEGAS — Fluocinolone acetonide and anti-VEGF treatment similarly reduce progression of proliferative diabetic retinopathy, according to a presentation here.“The duration of continuous ...

Iluvien was approved by the Food and Drug Administration back in 2014 for the treatment of DME in patients who were previously treated with corticosteroids without a clinically significant rise in ...

ILUVIEN has received marketing authorizations in Austria, the United Kingdom, Portugal, France, Germany and Spain and is commercially available in the United Kingdom and Germany.

ATLANTA — The U.S. Food and Drug Administration has issued a complete response letter to Alimera Sciences for its investigational sustained drug delivery system Iluvien, effectively denying ...

Alimera Sciences announced that the Food and Drug Administration (FDA) has approved Iluvien (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME) in ...

ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis IndicationsATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera ...